Eli Lilly and Company

Lilly Industries, Inc.

Winston S Marshall

Celia A Whitesitt

Jon Kevin Reel

Richard L Simon

Mitchell I Steinberg

Sherryl L Lifer

William Pfeifer

Alan David Palkowitz

Dennis Michael Zimmerman

K Jeff Thrasher

Donald B Boyd

John P Verge

Fariborz Mohamadi

George J Cullinan

Sandra K Sigmund

Jerome H Fleisch

Venkatraghavan Vasudevan

William B Lacefield

Kumiko Takeuchi

Kenneth Lee Hauser

John Goldsworthy

Robert D Dillard

Doris E McCullough

F Patrick Carr

Venkatraghaven Vasudevan

Holder

This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.

Angiotensin II antagonists

This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.

Angiotensin II antagonist intermediates

This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their methods of use for antagonizing angiotensin II receptors in mammals.

Angiotensin II antagonist 1,3-imidazoles and use thereas

The instant invention provides disubstituted tetrazoles that antagonizes the effect of leukotrienes C.sub.4, D.sub.4 or E.sub.4 or any combination thereof in selected tissues. The disubstituted tetrazoles are used in pharmaceutical formulations and methods of treatment of conditions caused by excessive release or production of leukotrienes C.sub.4, D.sub.4 or E.sub.4 or any combination thereof. Such conditions include an immediate hypersensitivity reaction of the type represented by asthma, or by shock or other adverse cardiovascular effects.

Disubstituted tetrazole leukotriene antagonists and methods for their

The instant invention provides disubstituted tetrazoles that antagonizes the effect of leukotrienes C.sub.4, D.sub.4 and E.sub.4 in selected tissues. The disubstituted tetrazoles are used in pharmaceutical formulations and methods of treatment of conditions caused by excessive amounts of leukotrienes C.sub.4, D.sub.4 or E.sub.4 or any combination thereof.

Disubstituted tetrazoles and their use as leukotriene antagonists

Resorcinol is acylated in a mixture of acetic or propionic acid and hydrobromic acid. The dihydroxy acylbenzenes thus produced are intermediates in the synthesis of leukotriene antagonists.

Process for intermediates to leukotriene antagonists

1,3-Dialkylbenzenes are acylated and deprotected in a mixture of acetic or propionic acid and hydrobromic acid. The dihydroxyphenones thus produced are intermediates in the synthesis of leukotriene antagonists.

Process for leukotriene antagonists

Growing community of inventors

Bargersville, IN, United States of America

Winston S Marshall